Venture Funding Deals: I-Mab Is The Mega-Round Leader With $220m Series C

Freeline Therapeutics, I-Mab Biopharma, Kaleido Biosciences and Precision BioSciences raised more than $100m each, but Chinese start-ups continue to bring in some of this year's largest venture capital mega rounds, with $220m in Series C cash to fund development of immuno-oncology and inflammatory disease drug candidates.

Venture Funding Reg column image

Derived from Strategic Transactions, Informa’s premium source for tracking life science deal activity, Venture Funding Deals provides a comprehensive monthly review of emerging biopharmaceutical companies that have raised venture capital. This month’s column covers financings announced in June.

SFC Co. Ltd. invested $15m into regenerative medicine firm AiVita Biomedical through the company's Series B round. Funds will...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Financing

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.